Evaluation of the Antimicrobial Activity In Vitro of Tigecycline in Comparison to Other Broad Spectrum Antibiotics in Isolates Collected From Patients

Wyeth is now a wholly owned subsidiary of Pfizer0 sites1,575 target enrollmentDecember 2005

ConditionsInfection

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Infection
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment: 1575
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.

Detailed Description

This is a prospective, microbiologic in vitro evaluation which will study the susceptibility of tigecycline in disk diffusion on clinical bacterial isolates collected from inpatients and outpatients. Fourteen hospital centers participated in the program. In vitro efficacy of tigecycline will be determined through the in vitro disk diffusion activity, using FDA breakpoints.

Registry

clinicaltrials.gov

Start Date

December 2005

End Date

September 2006

Last Updated

15 years ago

Study Type

Observational

Sex

All